Recent Updates
Recently added Catalysts
QURE

uniQure to Present at the RBC Capital Markets 2016 Global Healthcare Conference

Key Takeaway: AMSTERDAM, the Netherlands, Feb. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference on February 24, 2016 at 2:

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+425%
120-day peak, hindsight
Typical move
5.1%
average across 6 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
rAAV2/5-PBGD vector dosage 1
Phase 1 · Acute Intermittent Porphyria

Full Press Release Details

AMSTERDAM, the Netherlands, Feb. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference on February 24, 2016 at 2:05 p.m. EST / 20:05 pm CET. The conference is being held February 23 - 24, 2016 at The Palace Hotel in New York City.
The webcast, including a slide presentation, can be accessed through the following link: http://www.veracast.com/webcasts/rbc/healthcare2016/26211430508.cfm or by accessing the link displayed in the "Events" section on the "Media" page of the uniQure website at: http://www.uniqure.com/news/calendar-of-events/. The replay of the webcast will be available one hour after the conclusion of the live event and archived on the uniQure website for at least 30 days following the webcast.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
Last updated: Feb 15, 2016